Global Information
회사소개 | 문의 | 위시리스트

폐쇄성 수면무호흡증(OSA) : 시장 인사이트, 역학, 시장 예측(-2028년)

Obstructive Sleep Apnea (OSA) - Market Insights, Epidemiology and Market Forecast-2028

리서치사 DelveInsight Business Research LLP
발행일 2019년 08월 상품 코드 736660
페이지 정보 영문 145 Pages
가격
US $ 6,250 ₩ 7,591,000 PDF by E-mail (Single User License)
US $ 12,500 ₩ 15,182,000 PDF by E-mail (Site License)
US $ 18,750 ₩ 22,773,000 PDF by E-mail (Global License)


폐쇄성 수면무호흡증(OSA) : 시장 인사이트, 역학, 시장 예측(-2028년) Obstructive Sleep Apnea (OSA) - Market Insights, Epidemiology and Market Forecast-2028
발행일 : 2019년 08월 페이지 정보 : 영문 145 Pages

세계 주요 7개국의 폐쇄성 수면무호흡증(OSA) 총유병자수는 2017년에 1억 3,994만 8,725명, 시장 규모는 2억 2,180만 달러로 추산됩니다..

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 폐쇄성 수면무호흡증(OSA) 시장을 조사했으며, 시장 개요, 질병 배경, 기능·스테이지·그레이드·성별 유병수, 출시된 치료제 및 후보의약품 개요, 전체 및 국가별 시장 규모, 시장 성장 촉진요인 및 장벽 분석 등을 정리했습니다.

목차

제1장 주요 인사이트

제2장 폐쇄성 수면무호흡증(OSA) 시장 개요

  • 시장 점유율(실수치)
  • 시장 점유율(예측치)

제3장 질병 배경과 개요 : 폐쇄성 수면무호흡증(OSA)

  • 서론
  • 징조와 증상
  • 폐쇄성 수면무호흡증(OSA)의 스테이지
  • 병인과 위험인자
  • 병태생리
  • 바이오마커
  • 진단

제4장 역학과 환자 인구

  • 주요 조사 결과
  • 주요 7개국의 총유병수

제5장 폐쇄성 수면무호흡증(OSA) 역학 : 국가별

  • 미국
    • 유병률
    • 유병수 : 기능별
    • 유병수 : 스테이지별
    • 유병수 : 그레이드별
    • 유병수 : 성별
  • 유럽 5개국
    • 독일
      • 유병률
      • 유병수 : 기능별
      • 유병수 : 스테이지별
      • 유병수 : 그레이드별
      • 유병수 : 성별
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본

제6장 치료

  • 치료 목표
  • 치료 전략
  • NCCN 임상 진료 가이드라인에 기반한 치료 알고리즘

제7장 미충족 요구

제8장 출시된 의약품

  • 출시된 의약품 분석
  • Lutathera : Advanced Accelerator Applications
    • 제품 개요
    • 규제 마일스톤
    • 기타 개발 동향
    • 임상 개발
    • 안전성과 유효성
    • 제품 프로파일
  • Afinitor : Novartis Pharmaceutical
  • Somatuline Depot : Ipsen Pharma SAS
  • Sutent : Pfizer

제9장 기타 유망한 후보의약품

  • Surufatinib : Hutchison Medipharma Limited
    • 제품 개요
    • 기타 개발 동향
    • 임상 개발
    • 안전성과 유효성
    • 제품 프로파일
  • CVM-1118 : TaiRx, Inc.

제10장 주요 7개국의 폐쇄성 수면무호흡증(OSA) 시장 분석

  • 주요 조사 결과
  • 전체 시장 규모
  • 시장 규모 : 치료제별

제11장 국가별 시장 전망

  • 미국
  • 미국의 시장 규모
    • 전체 시장 규모
    • 시장 규모 : 치료제별
  • 유럽 5개국
  • 독일의 시장 규모
  • 프랑스의 시장 규모
  • 이탈리아의 시장 규모
  • 스페인의 시장 규모
  • 영국의 시장 규모
  • 일본
  • 일본의 시장 규모

제12장 시장 성장 촉진요인

제13장 시장 장벽

제14장 부록

  • 보고 방법

제15장 출전

제16장 DelveInsight의 서비스 내용

제17장 면책사항

제18장 DelveInsight 소개

KSM 19.08.16

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1 Prevalent Population of Obstructive Sleep Apnea in the 7MM (2017-2028)
  • Table 2 Total Adult Cases of Obstructive Sleep Apnea in the 7MM (2017-2028)
  • Table 3 Age-specific Prevalent Cases of Obstructive Sleep Apnea in the United States (2017-2028)
  • Table 4 Prevalence of OSA in Adults in the United States (2017-2028)
  • Table 5 Gender-specific Prevalence of Obstructive Sleep Apnea in the United States (2017-2028)
  • Table 6 Severity-specific Prevalent Cases of Obstructive Sleep Apnea in the United States (2017-2028)
  • Table 7 Prevalence of Clinical Manifestation of OSA in Adults in the United States (2017-2028)
  • Table 8 Diagnosed Cases of Obstructive Sleep Apnea in the United States (2017-2028)
  • Table 9 Prevalence of Obstructive Sleep Apnea in Germany by Age-group (2017-2028)
  • Table 10 Total Prevalence of Obstructive Sleep Apnea in Adults in Germany (2017-2028)
  • Table 11 Gender-specific Prevalence of Obstructive Sleep Apnea in Adults in Germany (2017-2028)
  • Table 12 Severity-specific prevalent cases of Obstructive Sleep Apnea in Germany (2017-2028)
  • Table 13 Prevalence of Clinical Manifestation of OSA in Adults in Germany (2017-2028)
  • Table 14 Diagnosed Cases of Obstructive Sleep Apnea in Germany (2017-2028)
  • Table 15 Age-specific Prevalence of Obstructive Sleep Apnea in France (2017-2028)
  • Table 16 Total Prevalence of Obstructive Sleep Apnea in France (2017-2028)
  • Table 17 Gender-specific Prevalent Cases of Obstructive Sleep Apnea in France (2017-2028)
  • Table 18 Severity Specific Prevalence of Obstructive Sleep Apnea in France (2017-2028)
  • Table 19 Prevalence of Clinical Manifestation of OSA in Adults in France (2017-2028)
  • Table 20 Diagnosed Cases of Obstructive Sleep Apnea in France (2017-2028)
  • Table 21 Prevalent Cases of Obstructive Sleep Apnea By Age-group in Italy (2017-2028)
  • Table 22 Total Prevalence of Obstructive Sleep Apnea in Adults in Italy (2017-2028)
  • Table 23 Gender-specific Prevalence of Obstructive Sleep Apnea in Italy (2017-2028)
  • Table 24 Severity-specific Prevalent Cases of Obstructive Sleep Apnea in Italy (2017-2028)
  • Table 25 Prevalence of Clinical Manifestation of OSA in Adults in Italy (2017-2028)
  • Table 26 Diagnosed Cases of Obstructive Sleep Apnea in Italy (2017-2028)
  • Table 27 Prevalent Cases of Obstructive Sleep Apnea by Age-group in Spain (2017-2028)
  • Table 28 Total Prevalence of Obstructive Sleep Apnea in Adults in Spain (2017-2028)
  • Table 29 Gender-specific Prevalence of Obstructive Sleep Apnea in Spain (2017-2028)
  • Table 30 Severity-specific Prevalent Cases of Obstructive Sleep Apnea in Spain (2017-2028)
  • Table 31 Prevalence of Clinical Manifestation of OSA in Adults in Spain (2017-2028)
  • Table 32 Diagnosed Cases of Obstructive Sleep Apnea in Spain (2017-2028)
  • Table 33 Prevalent Cases of Obstructive Sleep Apnea by Age-group in the United Kingdom (2017-2028)
  • Table 34 Total Prevalence of Obstructive Sleep Apnea in Adults the United Kingdom (2017-2028)
  • Table 35 Gender-specific Prevalence of OSA in the United Kingdom (2017-2028)
  • Table 36 Severity-specific Prevalent Cases of Obstructive Sleep Apnea in the UK (2017-2028)
  • Table 37 Prevalence of Clinical Manifestation of OSA in Adults in the UK (2017-2028)
  • Table 38 Diagnosed Cases of Obstructive Sleep Apnea in the United Kingdom(2017-2028)
  • Table 39 Age-Group Specific Prevalence of Obstructive Sleep Apnea in Japan (2017-2028)
  • Table 40 Total Prevalence of Obstructive Sleep Apnea in Adults Japan (2017-2028)
  • Table 41 Gender-specific Prevalence of Obstructive Sleep Apnea in Japan (2017-2028)
  • Table 42 Severity-specific Prevalent Cases of Obstructive Sleep Apnea in Japan (2017-2028)
  • Table 43 Prevalence of Clinical Manifestation of OSA in Adults in Japan (2017-2028)
  • Table 44 Diagnosed Cases of Obstructive Sleep Apnea in Japan (2017-2028)
  • Table 45 Provigil, Clinical Trial Description, 2019
  • Table 46 Solriamfetol, Clinical Trial Description, 2019
  • Table 47 Key cross competition- Emerging Therapies
  • Table 48 7 Major Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 49 Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 50 United States Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 51 Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 52 Germany Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 53 Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 54 France Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 55 Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 56 Italy Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 57 Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 58 Spain Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 59 Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 60 United Kingdom Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 61 Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 62 Japan Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Table 63 Therapy-Based Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)

List of Figures

  • Figure 1 Airway obstruction in Sleep Apnea
  • Figure 2 Apnea / hypopnea cycle
  • Figure 3 Pathological relationship between sleep apnea and cardiovascular disease
  • Figure 4 Risk Factors for Obstructive Sleep Apnea
  • Figure 5 Clinical algorithm for implementation of clinical practice guidelines.
  • Figure 6 Prevalent Population of Obstructive Sleep Apnea in the 7MM (2017-2028)
  • Figure 7 Total Adult OSA Cases in 7MM (2017-2028)
  • Figure 8 Prevalence of Obstructive Sleep Apnea by Age Group in the United States (2017-2028)
  • Figure 9 Prevalence of OSA in Adults in the United States (2017-2028)
  • Figure 10 Gender Specific Prevalence of Obstructive Sleep Apnea in the United States (2017-2028)
  • Figure 11 Severity-specific Prevalent Cases of Obstructive Sleep Apnea in the US (2017-2028)
  • Figure 12 Prevalence of Clinical Manifestation of OSA in Adults in the United States (2017-2028)
  • Figure 13 Diagnosed Cases of Obstructive Sleep Apnea in the United States (2017-2028)
  • Figure 14 Prevalence of Obstructive Sleep Apnea in Germany by Age Group (2017-2028)
  • Figure 15 Total Prevalence of Obstructive Sleep Apnea in Adults in Germany (2017-2028)
  • Figure 16 Gender Specific Prevalence of Obstructive Sleep Apnea in Adults in Germany (2017-2028)
  • Figure 17 Severity specific prevalent cases of Obstructive Sleep Apnea in Germany (2017-2028)
  • Figure 18 Prevalence of Clinical Manifestation of OSA in Adults in Germany (2017-2028)
  • Figure 19 Diagnosed Cases of Obstructive Sleep Apnea in Germany (2017-2028)
  • Figure 20 Prevalence of Obstructive Sleep Apnea in France by Age Group (2017-2028)
  • Figure 21 Total Prevalence of Obstructive Sleep Apnea in Adults in France (2017-2028)
  • Figure 22 Gender-specific Prevalent Cases of Obstructive Sleep Apnea in France (2017-2028)
  • Figure 23 Severity Specific Prevalence of Obstructive Sleep Apnea in France (2017-2028)
  • Figure 24 Prevalence of Clinical Manifestation of OSA in Adults in France (2017-2028)
  • Figure 25 Diagnosed Cases of Obstructive Sleep Apnea in France (2017-2028)
  • Figure 26 Prevalent Cases of Obstructive Sleep Apnea By Age Group in Italy (2017-2028)
  • Figure 27 Total Prevalence of Obstructive Sleep Apnea in Adults in Italy (2017-2028)
  • Figure 28 Gender-specific Prevalence of Obstructive Sleep Apnea in Italy (2017-2028)
  • Figure 29 Severity specific Prevalent Cases of Obstructive Sleep Apnea in Italy (2017-2028)
  • Figure 30 Prevalence of Clinical Manifestation of OSA in Adults in Italy (2017-2028)
  • Figure 31 Diagnosed Cases of Obstructive Sleep Apnea in Italy (2017-2028)
  • Figure 32 Prevalence of Obstructive Sleep Apnea by Age Group in Spain (2017-2028)
  • Figure 33 Total Prevalence of Obstructive Sleep Apnea in Adults in Spain (2017-2028)
  • Figure 34 Gender Specific Prevalence of Obstructive Sleep Apnea in Spain (2017-2028)
  • Figure 35 Severity specific Prevalent Cases of Obstructive Sleep Apnea in Spain (2017-2028)
  • Figure 36 Prevalence of Clinical Manifestation of OSA in Adults in Spain (2017-2028)
  • Figure 37 Diagnosed Cases of Obstructive Sleep Apnea in Spain (2017-2028)
  • Figure 38 Prevalent Cases of Obstructive Sleep Apnea in the United Kingdom (2017-2028)
  • Figure 39 Total Prevalence of Obstructive Sleep Apnea in Adults the United Kingdom (2017-2028)
  • Figure 40 Gender Specific Prevalence of OSA in the United Kingdom (2017-2028)
  • Figure 41 Severity specific Prevalent Cases of Obstructive Sleep Apnea in the UK (2017-2028)
  • Figure 42 Prevalence of Clinical Manifestation of OSA in Adults in the UK (2017-2028)
  • Figure 43 Diagnosed Cases of Obstructive Sleep Apnea in the United Kingdom (2017-2028)
  • Figure 44 Age Group Specific Prevalence of Obstructive Sleep Apnea in Japan (2017-2028)
  • Figure 45 Total Prevalence of Obstructive Sleep Apnea in Adults Japan (2017-2028)
  • Figure 46 Gender Specific Prevalence of Obstructive Sleep Apnea in Japan (2017-2028)
  • Figure 47 Severity specific Prevalent Cases of Obstructive Sleep Apnea in Japan (2017-2028)
  • Figure 48 Prevalence of Clinical Manifestation of OSA in Adults in Japan (2017-2028)
  • Figure 49 Diagnosed Cases of Obstructive Sleep Apnea in Japan (2017-2028)
  • Figure 50 Unmet Needs for Obstructive Sleep Apnea
  • Figure 51 7 Major Market Size of Obstructive Sleep Apnea in USD Million (2017-2028)
  • Figure 52 Therapy Based Market Size of OSA in 7MM in USD Million (2017-2028)
  • Figure 53 Market Size of Obstructive Sleep Apnea in the United States, USD Millions (2017-2028)
  • Figure 54 Therapy Based Market Size of OSA in USD Million (2017-2028)
  • Figure 55 Market Size of Obstructive Sleep Apnea in Germany, USD Millions (2017-2028)
  • Figure 56 Therapy Based Market Size of OSA in USD Million (2017-2028)
  • Figure 57 Market Size of Obstructive Sleep Apnea in France USD Millions (2017-2028)
  • Figure 58 Therapy Based Market Size of OSA in USD Million (2017-2028)
  • Figure 59 Market Size of Obstructive Sleep Apnea in Italy, USD Millions (2017-2028)
  • Figure 60 Therapy Based Market Size of OSA in USD Million (2017-2028)
  • Figure 61 Market Size of Obstructive Sleep Apnea in Spain, USD Millions (2017-2028)
  • Figure 62 Therapy Based Market Size of OSA in USD Million (2017-2028)
  • Figure 63 Market Size of Obstructive Sleep Apnea in the UK, USD Millions (2017-2028)
  • Figure 64 Therapy Based Market Size of OSA in USD Million (2017-2028)
  • Figure 65 Market Size of Obstructive Sleep Apnea in the UK, USD Millions (2017-2028)
  • Figure 66 Therapy Based Market Size of OSA in USD Million (2017-2028)
  • Figure 67 Market Drivers
  • Figure 68 Market Barriers

DelveInsight's 'Obstructive Sleep Apnea (OSA) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of OSA in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Obstructive Sleep Apnea (OSA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Obstructive Sleep Apnea (OSA) - Disease Understanding and Treatment Algorithm

The DelveInsight Obstructive Sleep Apnea (OSA) market report gives the thorough understanding of the Obstructive Sleep Apnea by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Obstructive Sleep Apnea in the US, Europe, and Japan.

Obstructive Sleep Apnea Epidemiology

The Obstructive Sleep Apnea (OSA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases by age-group, adult prevalent cases, gender-specific prevalent cases in adults, severity-specific prevalent cases in adults, clinical manifestations in adults and diagnosed cases of OSA in adults) scenario of Obstructive Sleep Apnea (OSA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent cases of Obstructive Sleep Apnea (OSA) in 7 MM was found to be 139,948,725, in the year 2017.

Obstructive Sleep Apnea Drug Chapters

This segment of the Obstructive Sleep Apnea report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The market forecast solely focuses on the market revenue generated by the pharmacological treatment (inclusive of Modafinil, marketed under the brand name Provigil, the R-isomer of modafinil, armodafinil present under the brand name Nuvigil (Teva)) used for the management of OSA. Detailed chapter for upcoming therapies like Solriamfetol (Jazz Pharmaceuticals) and Dronabinol (RespireRx) have been covered in the report.

Obstructive Sleep Apnea Market Outlook

The Obstructive Sleep Apnea market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Obstructive Sleep Apnea in 7MM was found to be USD 221.80 million in 2017, and is expected to increase at a CAGR of XX% from 2017-2028.

Obstructive Sleep Apnea Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Obstructive Sleep Apnea Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Obstructive Sleep Apnea Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Obstructive Sleep Apnea Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Obstructive Sleep Apnea market
  • Organize sales and marketing efforts by identifying the best opportunities for Obstructive Sleep Apnea market
  • To understand the future market competition in the Obstructive Sleep Apnea market.

Table of Contents

1. Key Insights

2. Obstructive Sleep Apnea Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Obstructive Sleep Apnea (OSA) in 2017
  • 2.2. Market Share (%) Distribution of Obstructive Sleep Apnea (OSA) in 2028

3. Disease Background and Overview: Obstructive Sleep Apnea (OSA)

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Staging of Obstructive Sleep Apnea (OSA)
  • 3.4. Etiology and Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Biomarkers
  • 3.7. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent Cases of OSA in 7MM countries

5. Country Wise-Epidemiology of OSA

  • 5.1. The United States
    • 5.1.1. Prevalence of OSA in the United States
    • 5.1.2. Functionality based Prevalence of OSA in the United States
    • 5.1.3. Stage-wise Prevalence of OSA in the United States
    • 5.1.4. Grade-wise Prevalence of OSA in the United States
    • 5.1.5. Gender-specific Prevalence of OSA in the United States
  • 5.2. EU5 Countries
  • 5.3. Germany
    • 5.3.1. Prevalence of OSA in Germany
    • 5.3.2. Functionality based Prevalence of OSA in Germany
    • 5.3.3. Stage-wise Prevalence of OSA in Germany
    • 5.3.4. Grade-wise Prevalence of OSA in Germany
    • 5.3.5. Gender-specific Prevalence of OSA in Germany
  • 5.4. France
    • 5.4.1. Prevalence of OSA in France
    • 5.4.2. Functionality based Prevalence of OSA in France
    • 5.4.3. Stage-wise Prevalence of OSA in France
    • 5.4.4. Grade-wise Prevalence of OSA in France
    • 5.4.5. Gender-specific Prevalence of OSA in France
  • 5.5. Italy
    • 5.5.1. Prevalence of OSA in Italy
    • 5.5.2. Functionality based Prevalence of OSA in Italy
    • 5.5.3. Stage-wise Prevalence of OSA in Italy
    • 5.5.4. Grade-wise Prevalence of OSA in Italy
    • 5.5.5. Gender-specific Prevalence of OSA in Italy
  • 5.6. Spain
    • 5.6.1. Prevalence of OSA in Spain
    • 5.6.2. Functionality based Prevalence of OSA in Spain
    • 5.6.3. Stage-wise Prevalence of OSA in Spain
    • 5.6.4. Grade-wise Prevalence of OSA in Spain
    • 5.6.5. Gender-specific Prevalence of OSA in Spain
  • 5.7. United Kingdom
    • 5.7.1. Prevalence of OSA in the UK
    • 5.7.2. Functionality based Prevalence of OSA in the UK
    • 5.7.3. Stage-wise Prevalence of OSA in the UK
    • 5.7.4. Grade-wise Prevalence of OSA in the UK
    • 5.7.5. Gender-specific Prevalence of OSA in The UK
  • 5.8. Japan
  • 5.9. Prevalence of OSA in Japan
  • 5.10. Functionality based Prevalence of OSA in Japan
  • 5.11. Stage-wise Prevalence of OSA in Japan
  • 5.12. Grade-wise Prevalence of OSA in Japan
  • 5.13. Gender-specific Prevalence of OSA in Japan

6. Treatment Practices

  • 6.1. Treatment Goals
  • 6.2. Treatment Strategy
  • 6.3. Treatment Algorithm based on NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines for Treatment

7. Unmet Needs

8. Marketed Products

  • 8.1. Marketed Drug Analysis
  • 8.2. Lutathera: Advanced Accelerator Applications
    • 8.2.1. Drug Description
    • 8.2.2. Regulatory Milestones
    • 8.2.3. Other Development Activities
    • 8.2.4. Clinical Development
    • 8.2.5. Safety and Efficacy
    • 8.2.6. Product Profile
  • 8.3. Afinitor: Novartis Pharmaceutical
    • 8.3.1. Drug Description
    • 8.3.2. Regulatory Milestones
    • 8.3.3. Other Development Activities
    • 8.3.4. Clinical Development
    • 8.3.5. Safety and Efficacy
    • 8.3.6. Product Profile
  • 8.4. Somatuline Depot: Ipsen Pharma S.A.S.
    • 8.4.1. Drug Description
    • 8.4.2. Regulatory Milestones
    • 8.4.3. Other Development Activities
    • 8.4.4. Clinical Development
    • 8.4.5. Safety and Efficacy
    • 8.4.6. Product Profile
    • 8.4.7. Other Somatostatin Analogues (SSAs)
  • 8.5. Sutent: Pfizer
    • 8.5.1. Drug Description
    • 8.5.2. Regulatory Milestones
    • 8.5.3. Other Development Activities
    • 8.5.4. Clinical Development
    • 8.5.5. Safety and Efficacy
    • 8.5.6. Product Profile

9. Other Promising Candidates

  • 9.1. Surufatinib: Hutchison Medipharma Limited
    • 9.1.1. Product Description
    • 9.1.2. Other development activities
    • 9.1.3. Clinical Development
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Product Profile
  • 9.2. CVM-1118: TaiRx, Inc.
    • 9.2.1. Product Description
    • 9.2.2. Other development activities
    • 9.2.3. Clinical Development
    • 9.2.4. Product Profile

10. Obstructive Sleep Apnea [OSA] Market Analysis: 7MM

  • 10.1. Key Findings
  • 10.2. Total Market Size of Pancreatic Neuroendocrine Tumor (OSA) in 7MM
  • 10.3. Market Size of OSA by Therapies in 7MM

11. Market Outlook by Country

  • 11.1. The United States: Market Outlook
  • 11.2. United States Market Size
    • 11.2.1. Total Market size of OSA
    • 11.2.2. OSA Market Size by Therapies
  • 11.3. EU-5 Countries: Market Outlook
  • 11.4. Germany Market Size
    • 11.4.1. Total Market size of OSA
    • 11.4.2. OSA Market Size by Therapies
  • 11.5. France Market Size
    • 11.5.1. Total Market size of OSA
    • 11.5.2. OSA Market Size by Therapies
  • 11.6. Italy Market Size
    • 11.6.1. Total Market size of OSA
    • 11.6.2. OSA Market Size by Therapies
  • 11.7. Spain Market Size
    • 11.7.1. Total Market size of OSA
    • 11.7.2. OSA Market Size by Therapies
  • 11.8. The United Kingdom Market Size
    • 11.8.1. Total Market size of OSA
    • 11.8.2. OSA Market Size by Therapies
  • 11.9. Japan: Market Outlook
  • 11.10. Japan: Market Size
    • 11.10.1. Total Market size of OSA
    • 11.10.2. OSA Market Size by Therapies

12. Market Drivers

13. Market Barriers

14. Appendix

  • 14.1. Report Methodology

15. Sources Used

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

1. Key Insights

2. Obstructive Sleep Apnea Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Obstructive Sleep Apnea (OSA) in 2017
  • 2.2. Market Share (%) Distribution of Obstructive Sleep Apnea (OSA) in 2028

3. Disease Background and Overview: Obstructive Sleep Apnea (OSA)

  • 3.1. Introduction
  • 3.2. Signs and Symptoms
  • 3.3. Staging of Obstructive Sleep Apnea (OSA)
  • 3.4. Etiology and Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Biomarkers
  • 3.7. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent Cases of OSA in 7MM countries

5. Country Wise-Epidemiology of OSA

  • 5.1. The United States
    • 5.1.1. Prevalence of OSA in the United States
    • 5.1.2. Functionality based Prevalence of OSA in the United States
    • 5.1.3. Stage-wise Prevalence of OSA in the United States
    • 5.1.4. Grade-wise Prevalence of OSA in the United States
    • 5.1.5. Gender-specific Prevalence of OSA in the United States
  • 5.2. EU5 Countries
  • 5.3. Germany
    • 5.3.1. Prevalence of OSA in Germany
    • 5.3.2. Functionality based Prevalence of OSA in Germany
    • 5.3.3. Stage-wise Prevalence of OSA in Germany
    • 5.3.4. Grade-wise Prevalence of OSA in Germany
    • 5.3.5. Gender-specific Prevalence of OSA in Germany
  • 5.4. France
    • 5.4.1. Prevalence of OSA in France
    • 5.4.2. Functionality based Prevalence of OSA in France
    • 5.4.3. Stage-wise Prevalence of OSA in France
    • 5.4.4. Grade-wise Prevalence of OSA in France
    • 5.4.5. Gender-specific Prevalence of OSA in France
  • 5.5. Italy
    • 5.5.1. Prevalence of OSA in Italy
    • 5.5.2. Functionality based Prevalence of OSA in Italy
    • 5.5.3. Stage-wise Prevalence of OSA in Italy
    • 5.5.4. Grade-wise Prevalence of OSA in Italy
    • 5.5.5. Gender-specific Prevalence of OSA in Italy
  • 5.6. Spain
    • 5.6.1. Prevalence of OSA in Spain
    • 5.6.2. Functionality based Prevalence of OSA in Spain
    • 5.6.3. Stage-wise Prevalence of OSA in Spain
    • 5.6.4. Grade-wise Prevalence of OSA in Spain
    • 5.6.5. Gender-specific Prevalence of OSA in Spain
  • 5.7. United Kingdom
    • 5.7.1. Prevalence of OSA in the UK
    • 5.7.2. Functionality based Prevalence of OSA in the UK
    • 5.7.3. Stage-wise Prevalence of OSA in the UK
    • 5.7.4. Grade-wise Prevalence of OSA in the UK
    • 5.7.5. Gender-specific Prevalence of OSA in The UK
  • 5.8. Japan
  • 5.9. Prevalence of OSA in Japan
  • 5.10. Functionality based Prevalence of OSA in Japan
  • 5.11. Stage-wise Prevalence of OSA in Japan
  • 5.12. Grade-wise Prevalence of OSA in Japan
  • 5.13. Gender-specific Prevalence of OSA in Japan

6. Treatment Practices

  • 6.1. Treatment Goals
  • 6.2. Treatment Strategy
  • 6.3. Treatment Algorithm based on NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines for Treatment

7. Unmet Needs

8. Marketed Products

  • 8.1. Marketed Drug Analysis
  • 8.2. Lutathera: Advanced Accelerator Applications
    • 8.2.1. Drug Description
    • 8.2.2. Regulatory Milestones
    • 8.2.3. Other Development Activities
    • 8.2.4. Clinical Development
    • 8.2.5. Safety and Efficacy
    • 8.2.6. Product Profile
  • 8.3. Afinitor: Novartis Pharmaceutical
    • 8.3.1. Drug Description
    • 8.3.2. Regulatory Milestones
    • 8.3.3. Other Development Activities
    • 8.3.4. Clinical Development
    • 8.3.5. Safety and Efficacy
    • 8.3.6. Product Profile
  • 8.4. Somatuline Depot: Ipsen Pharma S.A.S.
    • 8.4.1. Drug Description
    • 8.4.2. Regulatory Milestones
    • 8.4.3. Other Development Activities
    • 8.4.4. Clinical Development
    • 8.4.5. Safety and Efficacy
    • 8.4.6. Product Profile
    • 8.4.7. Other Somatostatin Analogues (SSAs)
  • 8.5. Sutent: Pfizer
    • 8.5.1. Drug Description
    • 8.5.2. Regulatory Milestones
    • 8.5.3. Other Development Activities
    • 8.5.4. Clinical Development
    • 8.5.5. Safety and Efficacy
    • 8.5.6. Product Profile

9. Other Promising Candidates

  • 9.1. Surufatinib: Hutchison Medipharma Limited
    • 9.1.1. Product Description
    • 9.1.2. Other development activities
    • 9.1.3. Clinical Development
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Product Profile
  • 9.2. CVM-1118: TaiRx, Inc.
    • 9.2.1. Product Description
    • 9.2.2. Other development activities
    • 9.2.3. Clinical Development
    • 9.2.4. Product Profile

10. Obstructive Sleep Apnea [OSA] Market Analysis: 7MM

  • 10.1. Key Findings
  • 10.2. Total Market Size of Pancreatic Neuroendocrine Tumor (OSA) in 7MM
  • 10.3. Market Size of OSA by Therapies in 7MM

11. Market Outlook by Country

  • 11.1. The United States: Market Outlook
  • 11.2. United States Market Size
    • 11.2.1. Total Market size of OSA
    • 11.2.2. OSA Market Size by Therapies
  • 11.3. EU-5 Countries: Market Outlook
  • 11.4. Germany Market Size
    • 11.4.1. Total Market size of OSA
    • 11.4.2. OSA Market Size by Therapies
  • 11.5. France Market Size
    • 11.5.1. Total Market size of OSA
    • 11.5.2. OSA Market Size by Therapies
  • 11.6. Italy Market Size
    • 11.6.1. Total Market size of OSA
    • 11.6.2. OSA Market Size by Therapies
  • 11.7. Spain Market Size
    • 11.7.1. Total Market size of OSA
    • 11.7.2. OSA Market Size by Therapies
  • 11.8. The United Kingdom Market Size
    • 11.8.1. Total Market size of OSA
    • 11.8.2. OSA Market Size by Therapies
  • 11.9. Japan: Market Outlook
  • 11.10. Japan: Market Size
    • 11.10.1. Total Market size of OSA
    • 11.10.2. OSA Market Size by Therapies

12. Market Drivers

13. Market Barriers

14. Appendix

  • 14.1. Report Methodology

15. Sources Used

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

Back to Top
전화 문의
F A Q